A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

NCT05732805 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Melanoma (Skin)
Melanoma Stage III
Melanoma Stage IV
Melanoma Unresectable
Melanoma Metastatic
Melanoma Advanced

Interventions

BIOLOGICAL: BCD-217
BIOLOGICAL: BCD-100
BIOLOGICAL: Placebo

Sponsor

Biocad